<DOC>
	<DOCNO>NCT01077830</DOCNO>
	<brief_summary>The purpose extension observe incidence rate cancer , total mortality , mortality due cancer 21 month follow-up period patient SEAS trial ( 2004_050 , MK0653A-043 ; NCT00092677 ) .</brief_summary>
	<brief_title>An Observational Follow-Up Study Incidence Cancer Mortality Patients From SEAS ( Simvastatin Ezetimibe Aortic Stenosis ) Trial ( MK-0653A-043-10 )</brief_title>
	<detailed_description>The SEAS Follow-up Study 21 month extension base protocol ( 2004_050 , MK0653A-043 ; NCT00092677 ) . The main objective extension observe incidence rate cancer , total mortality , mortality due cancer 21 month follow-up period ( 04-March 2008 31-December 2009 ) patient SEAS clinical trial . The source study data include data collect national cancer death registry well data original clinical trial . No patient visit occur . National cancer death registry exist 5 7 country participate base SEAS trial . At time Follow-up study initiation , access registry data Ireland feasible due local regulation Cancer Death registry exist Germany . As result , data collect SEAS patient know alive end base study originate Sweden , Denmark , Norway , Finland , United Kingdom .</detailed_description>
	<mesh_term>Ezetimibe , Simvastatin Drug Combination</mesh_term>
	<mesh_term>Ezetimibe</mesh_term>
	<mesh_term>Simvastatin</mesh_term>
	<criteria>The cohort include patient five participate country ( Sweden , Denmark , Norway , Finland , United Kingdom ) randomize SEAS base study know alive end base study</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>New Incidence Cancer</keyword>
</DOC>